BY OUR PLATFORMS
BY THERAPEUTIC AREA
BY RESEARCH STAGE
By Javier Terriente, Co-Founder/CDD at ZeClinics and Co-Founder/CSO at ZeCardio Therapeutics.
Javier is expert in zebrafish biology and drug discovery. Co-Founder of ZeClinics and ZeCardioTX. 20 year of research experience. 7 years supervising research teams. VP at Asebio.
When discussing which should be the first article of this news, we came up with several topics. All of them aimed at reflecting the work we develop at ZeClinics: “How to use zebrafish for this…” or “Why zebrafish is a useful tool for that…”. Soon, we realized this collection of articles should start by the primary question (and we don’t mean why we are in the universe): Why do we use zebrafish at ZeClinics?
For us it is obvious how great zebrafish is for drug and target discovery. Nevertheless, it might not be so much for those not familiarized with the model. Thus, as it happens with all good stories, we should start at the beginning.
Circa 2013, four academic scientists (Simone Calzolari, Ignasi Sahún, Davide D’Amico and Javier Terriente) decided to build a biotech company. Some of us already had a vast experience in the use of zebrafish. As academics, we were exploiting zebrafish experimental and biological advantages for understanding the genetic basis underlying brain development. We had started working with this model under the assumption that zebrafish would provide the experimental simplicity of invertebrate models, while allowing a higher translatability towards human biology. We might be rarely right, but in that case we were spot on.
We knew the model was brilliant for academic research. Would it be as good for modelling human disease and discovering new drugs in an industrial setting?
We don’t like spoilers, but the answer is YES. Now, let’s explain why:
The aforementioned experimental and biological advantages make obvious why the zebrafish model is the perfect tool, for the pharma and chemical industry, for understanding chemical toxicity, drug efficacy research and human diseases modelling and understanding. But we still had to prove the model provides biological translatability. Which is to say: are we sure results obtained in zebrafish predict genetic and pharmacological outcomes in humans?
To address that important aspect, we have published several validation articles and reviews in peer-review journals; and all our services have been validated with standards. So yes, we are pretty certain the model is predictive. Most importantly, our R&D efforts are always active: to keep validating the model, to create new tools and services, and to discover our own therapeutics, as we are already doing in our first spin-out company ZeCardio Therapeutics.
We believe in the power of zebrafish for understanding disease and discovering new therapeutics but, importantly, we provide data supporting this assumption.
So… why does ZeClinics use zebrafish? That original question started our company and still fuels our news. In the coming months, this news will be a window to ZeClinics’ scientists, news, and activities. We will showcase our research, providing the “what for”, the “why”, the “how”, and the “what’s next” around the zebrafish model.
For those who want to know more about zebrafish, stay tuned, and reach out if curious. We will be happy to discuss the pros, the cons, and all those unrelated questions that make news fascinating.